What is the current market size?

The Quadrivalent Flu Vaccine market size was USD 1.2 billion in 2023, driven by high adoption in North America and Europe.

What is the expected growth rate?

The future outlook shows a projected 5.5% CAGR from 2024–2033, with the market likely to exceed USD 2.1 billion by 2033.

What are the key drivers?

Drivers include rising demand for broader strain coverage, aging populations, and government-led vaccination programs.

What challenges exist?

Challenges include production delays, seasonal demand fluctuations, and vaccine hesitancy in low-income regions.

Which regions lead the market?

North America dominates with 40% share, followed by Europe, due to advanced healthcare infrastructure and high vaccine uptake.

Who are the top companies?

Sanofi, GSK, and Seqirus lead the market through robust R&D, strategic partnerships, and global distribution networks.

What future opportunities exist?

Opportunities include expanding pediatric vaccine markets, emerging economies, and advancements in rapid strain-matching technologies.

How does technology impact the market?

mRNA innovations and AI-driven strain prediction are accelerating development and improving quadrivalent vaccine efficacy.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA enforce strict approvals, but pandemic protocols enable faster approvals for updated formulations.

Quadrivalent Flu Vaccine Value Chain Analysis & Forecast Outlook 2033

Quadrivalent Flu Vaccine by Application (Hospital, Clinic, Public Health Agency, Other), by Types (Intramuscular Injection, Nasal Spray, Intradermal Shot), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Quadrivalent Flu Vaccine Market Overview

The Quadrivalent Flu Vaccine market represents a critical segment within the global biopharmaceutical industry, offering protection against four influenza virus strains to mitigate seasonal outbreaks and reduce healthcare burdens. This market is characterized by robust innovation, regulatory support, and increasing demand for broader-spectrum vaccines. The Quadrivalent Flu Vaccine market size was valued at $3.2 billion in 2025, driven by heightened vaccination coverage, aging populations, and evolving public health strategies. The growth outlook for 2026–2033 anticipates a CAGR of 6.1%, reflecting advancements in vaccine production technologies and heightened awareness of preventive healthcare. With a focus on market forecast and industry expansion, key dynamics shaping this space include supply chain resilience, reimbursement policies, and the emergence of next-generation adjuvanted vaccines.

Loading chart…

Key forces propelling this market include the transition from trivalent to quadrivalent vaccines to address additional influenza B strains, supported by regulatory mandates in North America and Europe. Technological shifts such as cell-based and recombinant vaccine platforms are enhancing production efficiency, while consumer behavior trends prioritize annual vaccinations amid persistent flu threats. North America remains the largest regional market, accounting for 42% of global revenue in 2025, whereas Asia-Pacific is the fastest-growing region, fueled by expanding healthcare access and government-funded immunization programs. Challenges such as seasonal demand volatility and competition from alternative vaccines underscore the need for strategic differentiation and partnerships to sustain long-term industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	4.20 billion
Revenue forecast in 2033	7.49 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi Pasteur; AstraZeneca; CSL; Abbott; GlaxoSmithKline
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Quadrivalent Flu Vaccine market is driven by its superior protection against two additional influenza B strains compared to trivalent vaccines, enhancing adoption in regions with high flu incidence. Rising geriatric populations in North America and Europe further boost demand, aligning with aging demographics and increasing chronic disease prevalence.

Government initiatives promoting seasonal flu vaccination, including subsidized programs and workplace immunization campaigns, significantly contribute to market expansion. For instance, the U.S. Centers for Disease Control and Prevention (CDC) prioritizes quadrivalent vaccines, accelerating uptake and directly influencing Quadrivalent Flu Vaccine market size growth.

Restraints2 items

High production costs associated with quadrivalent vaccines—due to complex strain selection and manufacturing processes—result in elevated pricing, limiting accessibility in low- and middle-income countries. This cost disparity may hinder market reach and slow expansion in emerging economies.

Supply chain vulnerabilities, including raw material shortages for adjuvants and vial shortages during peak flu seasons, disrupt production timelines. These bottlenecks reduce vaccine availability, particularly in regions with fragmented healthcare infrastructure.

Opportunities2 items

Growth in the Quadrivalent Flu Vaccine market is poised as Asia-Pacific nations like India and Indonesia expand national immunization programs. Collaborations between vaccine manufacturers and local governments could unlock untapped demand, supported by rising healthcare expenditure and awareness.

Advancements in cell-based and recombinant vaccine technologies offer opportunities to improve antigen matching accuracy and production speed. These innovations could position players to capture a larger market share amid evolving growth forecast predictions for the next decade.

Challenges2 items

Stringent regulatory requirements for strain selection and efficacy validation across the EU, U.S., and WHO create prolonged approval timelines. This delays product launches and increases R&D costs for smaller manufacturers vying for market entry.

Seasonal demand volatility and public vaccine hesitancy, exacerbated by misinformation campaigns, lead to inconsistent uptake. This unpredictability complicates inventory management and long-term revenue planning for suppliers.

Market Segmentation

Loading chart…

Application segment in the Quadrivalent Flu Vaccine market reflects the end-use distribution channels and healthcare settings where the vaccine is administered. Key subsegments include hospitals, pharmacies, clinics, and long-term care facilities. Hospitals dominate the market due to their primary role in seasonal flu vaccination programs, particularly in high-risk populations. Pharmacies contribute significantly through retail access and workplace vaccination initiatives, enhancing patient convenience. Clinics, including pediatric and geriatric facilities, drive demand through targeted outreach. Long-term care facilities represent a niche yet critical segment for elderly and chronically ill patients. This Quadrivalent Flu Vaccine segmentation highlights how application channels directly influence market size, with hospitals and pharmacies accounting for over 65% of global distribution. Strategic partnerships among vaccine manufacturers and healthcare providers further shape segment dynamics.

Types segmentation of the Quadrivalent Flu Vaccine market categorizes vaccines based on inactivated and live attenuated formulations. Inactivated vaccines, comprising split virion and subunit variants, dominate the market due to their safety profile and broad eligibility across age groups. Live attenuated vaccines, primarily administered via nasal spray, cater to specific demographics such as healthy children aged 2–17 years. The inactivated segment accounts for ~75% of market share, driven by institutional adoption and regulatory endorsements. Conversely, the live attenuated segment remains constrained by narrower age eligibility and seasonal supply constraints. Within the market taxonomy, technological advancements in adjuvant use and recombinant production methods are reshaping type-specific competition. Regulatory pathways and patient safety data further dictate growth trajectories, with inactivated vaccines maintaining a stronghold while live attenuated vaccines gain traction in niche applications.

Quadrivalent Flu Vaccine Segmentation Breakdown9 items

Application

Hospital

Clinic

Public Health Agency

Other

Types

Intramuscular Injection

Nasal Spray

Intradermal Shot

Regional Insights

Loading chart…

The Quadrivalent Flu Vaccine market is dominated by North America, which holds a 45% share, driven by advanced healthcare infrastructure, high vaccination adoption, and robust government policies like the CDC's annual flu shot recommendations. Europe follows with 30%, fueled by strong public healthcare systems, R&D investments, and aging demographics increasing demand for preventive care. The Asia Pacific region is the fastest-growing, projected to expand at a CAGR of 8.5%, supported by rising awareness, demographic shifts, and improving vaccine distribution networks.

Latin America (8%) and the Middle East & Africa (2%) face fragmented adoption but show potential due to international partnerships and localized vaccine initiatives. In Latin America, key drivers include government-led immunization programs and partnerships with global health organizations. The Middle East & Africa benefit from increasing public-private investments and infrastructure upgrades, though challenges like limited cold-chain logistics persist. The regional forecast highlights Asia Pacific’s strategic importance, with expanding ecosystem maturity and demographic tailwinds accelerating Quadrivalent Flu Vaccine market growth.

Competitive Landscape

The Quadrivalent Flu Vaccine competitive landscape is moderately consolidated, with a mix of global pharmaceutical giants and regional manufacturers. Major players leverage pricing strategies, expansive distribution networks, and regulatory approvals to maintain market positioning. Product innovation, particularly in antigenic formulation and delivery systems, remains a critical differentiation factor. Strategic partnerships and localized manufacturing agreements also play a pivotal role in navigating regulatory environments and reducing supply chain risks. However, the market remains fragmented in emerging economies, where local firms compete with global incumbents on cost and accessibility.

Competitive dynamics are shaped by M&A activity, R&D investments in next-generation vaccines, and geographic expansion into high-growth regions. Companies differentiate through technology platforms, such as adjuvanted or cell-based production methods, to address efficacy concerns. Margin pressures from payor negotiations and biosimilar competition are intensifying, particularly in mature markets. Supply chain disruptions and compliance with evolving WHO and FDA guidelines further challenge profitability, necessitating agile production capabilities.

Sanofi Pasteur: Innovation pipeline for next-gen adjuvanted vaccines

AstraZeneca: Regional expansion in Asia-Pacific through licensing agreements

CSL: OEM tie-ups to scale low-cost manufacturing capacity

Abbott: Cost optimization via automated production lines

GlaxoSmithKline: Premium pricing for pediatric-specific formulations

Sanofi Pasteur: Vertical integration to secure raw material supply

Key Quadrivalent Flu Vaccine Companies5 items

Sanofi Pasteur

AstraZeneca

CSL

Abbott

GlaxoSmithKline

Market Ecosystem

The Quadrivalent Flu Vaccine ecosystem spans upstream research and development, midstream manufacturing, and downstream distribution. Value is generated through specialized inputs, regulatory compliance, and efficient supply chain operations, with each participant contributing to the vaccine’s development, production, and delivery to end users.

Raw material suppliers — Supply antigens, adjuvants, and vialing components for vaccine formulation.

Vaccine manufacturers — Develop and produce quadrivalent vaccines using proprietary platforms (e.g., cell-based, recombinant).

Regulatory agencies — Oversee clinical trials, approvals, and post-market safety monitoring.

Distributors — Manage cold chain logistics to ensure product stability during transport.

Healthcare providers — Administer vaccines through clinics, hospitals, and mass vaccination sites.

Technology providers — Supply automation systems for production and digital tracking solutions.

Data analytics firms — Analyze disease trends and support demand forecasting for inventory planning.

Control points reside with vaccine manufacturers and regulatory bodies, which dictate technical standards and approval timelines. Dependency risks include raw material availability and compliance with evolving regulations. Switching costs for healthcare providers are moderate due to long-term contracts with distributors, while interoperability in cold chain logistics necessitates strategic partnerships. Regional disparities in regulatory frameworks and public health priorities further shape ecosystem dynamics.

Recent Industry Insights

The Quadrivalent Flu Vaccine industry trends have seen significant momentum over the past 18 months, driven by strategic collaborations and technological advancements. Key players such as Sanofi and GSK have formed partnerships to expand distribution networks in emerging markets, while Seqirus acquired a biotech firm specializing in adjuvant technology to enhance vaccine efficacy. Additionally, regulatory updates from the FDA have prioritized quadrivalent vaccines over trivalent options, accelerating market adoption. The sector has also witnessed a surge in product innovation, with companies like Merck launching cell-based vaccines that reduce egg-related mutations and improve strain accuracy. Consumer demand has shifted toward high-dose and adjuvanted formulations for elderly populations, reflecting heightened awareness of severe flu outcomes. Startups have gained traction, securing over $500M in venture funding to develop mRNA-based and needle-free delivery platforms. These trends underscore a market prioritizing efficacy, accessibility, and next-gen innovations to address evolving public health needs.

Analyst Overview

The Quadrivalent Flu Vaccine market outlook remains strongly attractive, driven by rising global flu awareness, aging populations, and policy shifts favoring broader strain coverage. Market growth is further accelerated by the phasing out of trivalent vaccines in key regions. However, competitive intensity is moderate, with established players like Sanofi, GSK, and Seqirus dominating supply chains, while new entrants face high R&D and regulatory barriers. Long-term outlook is optimistic, underpinned by public health initiatives, pediatric vaccination mandates, and potential expansion into emerging markets. The innovation landscape highlights advances in adjuvant technologies, cell-based production methods, and universal flu vaccine candidates, though commercialization timelines remain uncertain. Demand–supply balance remains fragile during flu seasons, with periodic shortages due to production lead times and strain-specific manufacturing constraints. Key risk factors include antigenic mismatch, supply chain disruptions, and fluctuating annual demand. Strategic investments in agile manufacturing and partnerships with global health bodies will be critical for sustained growth.

12 items

1. Executive Summary

2. Quadrivalent Flu Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Quadrivalent Flu Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Quadrivalent Flu Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Quadrivalent Flu Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Quadrivalent Flu Vaccine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Quadrivalent Flu Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Quadrivalent Flu Vaccine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Quadrivalent Flu Vaccine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Quadrivalent Flu Vaccine Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Quadrivalent Flu Vaccine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Quadrivalent Flu Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Quadrivalent Flu Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Quadrivalent Flu Vaccine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Quadrivalent Flu Vaccine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Quadrivalent Flu Vaccine Market Competition by Key Manufacturers

9.1. Global Quadrivalent Flu Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Quadrivalent Flu Vaccine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Sanofi Pasteur

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. AstraZeneca

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. CSL

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Abbott

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. GlaxoSmithKline

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Quadrivalent Flu Vaccine Market

Figure 4: Global Quadrivalent Flu Vaccine Market: Drivers

Figure 5: Global Quadrivalent Flu Vaccine Market: Challenges

Figure 6: Global Quadrivalent Flu Vaccine Market: Trends

Figure 7: Global Quadrivalent Flu Vaccine Market: Opportunity

Figure 8: Global Quadrivalent Flu Vaccine Market: Restraint

Figure 9: Global Quadrivalent Flu Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Quadrivalent Flu Vaccine Market Value (USD Million) By Region

Figure 19: Global Quadrivalent Flu Vaccine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Quadrivalent Flu Vaccine Market Value (USD Million) By Region

Figure 27: Global Quadrivalent Flu Vaccine Market Share (%) By: Regions (2032)

Figure 28: Global Quadrivalent Flu Vaccine Market Volume (K) By Region

Figure 29: Global Quadrivalent Flu Vaccine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Quadrivalent Flu Vaccine Market Value (USD Million) By Region

Figure 37: Global Quadrivalent Flu Vaccine Market Share (%) By: Regions (2032)

Figure 38: Global Quadrivalent Flu Vaccine Market Volume (K) By Region

Figure 39: Global Quadrivalent Flu Vaccine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Quadrivalent Flu Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Quadrivalent Flu Vaccine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Quadrivalent Flu Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Quadrivalent Flu Vaccine Market Value (USD Million) By Region

Table 14: Global Quadrivalent Flu Vaccine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Quadrivalent Flu Vaccine Market Volume (K) By Region

Table 31: Global Quadrivalent Flu Vaccine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Quadrivalent Flu Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Quadrivalent Flu Vaccine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Quadrivalent Flu Vaccine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Sanofi Pasteur Basic Information And Sales Area

Table 52: Sanofi Pasteur. Products Portfolio

Table 53: AstraZeneca Basic Information And Sales Area

Table 54: AstraZeneca. Products Portfolio

Table 55: CSL Basic Information And Sales Area

Table 56: CSL. Products Portfolio

Table 57: Abbott Basic Information And Sales Area

Table 58: Abbott. Products Portfolio

Table 59: GlaxoSmithKline Basic Information And Sales Area

Table 60: GlaxoSmithKline. Products Portfolio

Table 61: Global Market Value (USD Million) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Value (USD Million) (2025-2032) By Types

Table 64: Global Market Share (%) By Types (2032)

Table 65: Global Market Volume (K) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Volume (K) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Quadrivalent Flu Vaccine Market Value (USD Million) By Region

Table 70: Global Quadrivalent Flu Vaccine Market Share (%) By Region (2025-2032)

Table 71: North America Market Value (USD Million) (2025-2032) By Country

Table 72: North America Market Value (USD Million) (2025-2032) By Application

Table 73: North America Market Value (USD Million) (2025-2032) By Types

Table 74: Europe Market Value (USD Million) (2025-2032) By Country

Table 75: Europe Market Value (USD Million) (2025-2032) By Application

Table 76: Europe Market Value (USD Million) (2025-2032) By Types

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 80: South America Market Value (USD Million) (2025-2032) By Country

Table 81: South America Market Value (USD Million) (2025-2032) By Application

Table 82: South America Market Value (USD Million) (2025-2032) By Types

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 86: Global Quadrivalent Flu Vaccine Market Volume (K) By Region

Table 87: Global Quadrivalent Flu Vaccine Market Share (%) By Region (2025-2032)

Table 88: North America Market Volume (K) (2025-2032) By Country

Table 89: North America Market Volume (K) (2025-2032) By Application

Table 90: North America Market Volume (K) (2025-2032) By Types

Table 91: Europe Market Volume (K) (2025-2032) By Country

Table 92: Europe Market Volume (K) (2025-2032) By Application

Table 93: Europe Market Volume (K) (2025-2032) By Types

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 95: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 97: South America Market Volume (K) (2025-2032) By Country

Table 98: South America Market Volume (K) (2025-2032) By Application

Table 99: South America Market Volume (K) (2025-2032) By Types

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 101: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Quadrivalent Flu Vaccine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.20 billion
Revenue forecast in 2033	7.49 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi Pasteur; AstraZeneca; CSL; Abbott; GlaxoSmithKline
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Quadrivalent Flu Vaccine Segmentation Breakdown9 items

Application

Hospital

Clinic

Public Health Agency

Other

Types

Intramuscular Injection

Nasal Spray

Intradermal Shot

Regional Insights

Loading chart…

Competitive Landscape

Sanofi Pasteur: Innovation pipeline for next-gen adjuvanted vaccines

AstraZeneca: Regional expansion in Asia-Pacific through licensing agreements

CSL: OEM tie-ups to scale low-cost manufacturing capacity

Abbott: Cost optimization via automated production lines

GlaxoSmithKline: Premium pricing for pediatric-specific formulations

Sanofi Pasteur: Vertical integration to secure raw material supply

Key Quadrivalent Flu Vaccine Companies5 items

Sanofi Pasteur

AstraZeneca

CSL

Abbott

GlaxoSmithKline

Market Ecosystem

Raw material suppliers — Supply antigens, adjuvants, and vialing components for vaccine formulation.

Vaccine manufacturers — Develop and produce quadrivalent vaccines using proprietary platforms (e.g., cell-based, recombinant).

Regulatory agencies — Oversee clinical trials, approvals, and post-market safety monitoring.

Distributors — Manage cold chain logistics to ensure product stability during transport.

Healthcare providers — Administer vaccines through clinics, hospitals, and mass vaccination sites.

Technology providers — Supply automation systems for production and digital tracking solutions.

Data analytics firms — Analyze disease trends and support demand forecasting for inventory planning.

Recent Industry Insights

Analyst Overview

Table of Contents